Company Announcements

etherna LNP Formulations: Implications for CDMO Manufacturing of mRNA Vaccines

A recent peer-reviewed paper from etherna demonstrates enhanced immune response and reduced reactogenicity of LNP-based mRNA vaccines, signaling new growth avenues for CDMOs specializing…

December 23, 2025

Company Announcements

Leveraging Standardized Viral Vector Platforms to Elevate CDMO Service

Explore how standardized viral vector platforms enable CDMOs to improve process efficiency, regulatory compliance, and capacity scalability in gene therapy production.

December 23, 2025

Company Announcements

Just – Evotec Biologics and ABL Deepen CDMO Partnership for HIV bnAb Development

Just – Evotec Biologics has deepened its development and manufacturing agreement with Advanced BioScience Laboratories (ABL), advancing CDMO capabilities for broadly neutralising HIV antibodies.

December 23, 2025

Company Announcements

Sharp Services Commits to SBTi: CDMO Sustainability Strategies for Emissions Reduction

Sharp Services, a leader in pharmaceutical packaging and clinical trial supply, has joined the Science Based Targets initiative to drive greenhouse gas reductions. Discover…

December 23, 2025

Company Announcements

Evotec SE Conference Call Signals Strategic Shifts in CDMO Landscape

Evotec SE’s upcoming conference call on January 22, 2024, will provide a business update with significant CDMO implications, covering outsourcing strategies, manufacturing capacity, and…

December 23, 2025

Company Announcements

Modern Scalable Bioreactors: A CDMO Strategy for Gene and Cell Therapy Success

An in-depth examination of modern scalable bioreactor platforms and their strategic role in CDMO-driven gene and cell therapy manufacturing.

December 22, 2025

Company Announcements

Designing Stable Cell Line Strategies for Gene and Cell Therapy Manufacturing in a CDMO Environment

A detailed guide for CDMOs on designing robust stable cell line strategies for gene and cell therapy manufacturing, covering technical, regulatory, and operational considerations.

December 22, 2025

Company Announcements

Evotec and Crohn’s & Colitis Foundation Partnership Drives CDMO Opportunities for IBD Therapies

Evotec’s alliance with the Crohn’s & Colitis Foundation signals intensified CDMO engagement in IBD drug development, highlighting opportunities in outsourcing, manufacturing scale-up, technology integration,…

December 22, 2025

Company Announcements

Evotec-BMS Neuroscience Partnership: CDMO Implications

Evotec’s latest $25 million funding milestone with Bristol Myers Squibb highlights critical trends in neuroscience contract development and manufacturing, underscoring investment shifts, capacity demands,…

December 22, 2025

Company Announcements

Evotec and Owkin Forge AI-Driven Partnership: Implications for CDMO Services

Evotec and Owkin’s AI-integrated collaboration in oncology and I&I is poised to reshape CDMO outsourcing strategies, drive demand for advanced manufacturing services, and accelerate…

December 21, 2025